- Reaction score
- 3,025
17-alpha, alfatradiol, is what is used in ell-cranell/Pantostin. It’s clinically proven to increase anagen hair counts. In fact, it’s bee used to treat male pattern baldness in women who have undergone aromatase inhibition for breast cancer. It isn’t bad for hair.
Estriol is the weakest bio available form of estrogen, and is a metabolite of estrogen. If estrogen is poor, estriol is even more so. Receptors have the highest affinity for 17b.
I agree and EE is not healthy and not normal. I also agree that it has a low affinity to estrogenic tissues because of its synthetic nature. I am willing to try a dose of 4mg 17b/100mg prometrium for a while but I’ll need to get the latter online.
I just found another reason for you to get off of ethinyl estradiol which connects to this same principle of differential ER-alpha vs. ER-beta activation:
Estrogen receptor alpha regulates matrix metalloproteinase-13 promoter activity
Many females develop bone diseases such as osteoporosis, and joint diseases such as osteoarthritis after menopause when estrogen levels decline. As estrogen receptors (ER) are present in such tissues, it is possible that the loss of estrogen at menopause influences the expression of enzymes such as members of the MMP family of proteinases to affect bone and connective tissue metabolism. The present study was undertaken to assess a possible relationship between ER-α and MMP-13 expression at the promoter level, and to determine how such a relationship could be modulated by ligands such as estrogen. Using a rabbit synovial cell line lacking endogenous ER, a transient transfection system with an ER-α construct, and a series of MMP-13 promoter-luciferase constructs of varying lengths and with specific mutations in transcription factor binding sites, it was found that ER-α can significantly enhance MMP-13 promoter activity via the AP-1 site, with modulatory influences by the Runx and PEA-3 sites on this ER-α dependent enhancement of the promoter activity. This enhancement by ER-α was significantly depressed in the presence of 17-ß-estradiol in a dose dependent manner. The influence of tamoxifen and raloxifen on the activity of the ER-α was consistent with their known agonist/antagonist activity. These findings indicate that loss of estrogen in vivo could potentially lead to enhanced expression of MMP-13, a proteinase that has been implicated in both osteoporosis and osteoarthritis, and thus contribute to the development and progression of these conditions.
https://linkinghub.elsevier.com/retrieve/pii/S0925-4439(06)00112-8
Many females develop bone diseases such as osteoporosis, and joint diseases such as osteoarthritis after menopause when estrogen levels decline. As estrogen receptors (ER) are present in such tissues, it is possible that the loss of estrogen at menopause influences the expression of enzymes such as members of the MMP family of proteinases to affect bone and connective tissue metabolism. The present study was undertaken to assess a possible relationship between ER-α and MMP-13 expression at the promoter level, and to determine how such a relationship could be modulated by ligands such as estrogen. Using a rabbit synovial cell line lacking endogenous ER, a transient transfection system with an ER-α construct, and a series of MMP-13 promoter-luciferase constructs of varying lengths and with specific mutations in transcription factor binding sites, it was found that ER-α can significantly enhance MMP-13 promoter activity via the AP-1 site, with modulatory influences by the Runx and PEA-3 sites on this ER-α dependent enhancement of the promoter activity. This enhancement by ER-α was significantly depressed in the presence of 17-ß-estradiol in a dose dependent manner. The influence of tamoxifen and raloxifen on the activity of the ER-α was consistent with their known agonist/antagonist activity. These findings indicate that loss of estrogen in vivo could potentially lead to enhanced expression of MMP-13, a proteinase that has been implicated in both osteoporosis and osteoarthritis, and thus contribute to the development and progression of these conditions.
https://linkinghub.elsevier.com/retrieve/pii/S0925-4439(06)00112-8
So not only is the abnormal ER-alpha stimulation terrible for hair growth because it induces catagen (cessation of growth), it may also lead to osteoporosis and osteoarthritis over time. As someone who enjoys the gym and physical activity, this is something you would not want to have to face long term from your current synthetic hormonal profile.
I tried to find data on 17 alpha-estrogen and how it affects ER-alpha vs ER-beta receptors but could not. When dealing with a known agent vs. an unknown agent, I would always prefer to stick to the known agents. And the known agents in this case (eg. 17 beta-estradiol, estriol) are also far easier to get prescriptions for anyway.
On that note, from all this data, I can also now answer a question which I couldn't before: Which is better? Triest or Biest?
Triest features estradiol/estriol/estrone while Biest has estradiol/estriol only.
Given the greater alpha stimulation of estrone it would seem estrone is relatively useless (and even potentially harmful). This may be why many hormone sites describe estrone as the "ugly estrogen". Thus Biest is the most ideal treatment for menopausal hormone replacement.
Dosages are reviewed here:
https://www.womensinternational.com/wp-content/uploads/2017/06/Female-Hormone-Chart.pdf
Biest is traditionally 80% estriol, 20% estradiol, which is perfect to try to maximize the ER-beta stimulation from estriol. Again, only estriol preferentially stimulates ER-beta which is what we want. Estradiol stimulates ER-alpha and ER-beta equally. The reason Biest is so heavily weighted to estriol (80% composition) is exactly what you said - estriol is weak, so you need more of it to get a decent effect from it. Estriol also has a short half life.
You would yet again be selling yourself short if you only took 17 beta-estradiol without estriol. With just estradiol, you will have equal ER-alpha and ER-beta stimulation (which would certainly be much, much better than the only ER-alpha stimulation you're getting now from Diane 35). But with a standard Biest preparation, you'd be getting some extra ER-beta stimulation which should give you the absolute best results for your hair and long term health.
I would call around more hormone replacement clinics and naturopaths until you can find someone willing to prescribe Biest to you. Try not to scare anyone you meet with your medical history - if they think you're too "complex" they might not want to touch you for fear of liability. I would simply tell them you have POF, are unhappy on Diane 35, worry about your long term health on synthetic hormones, and you'd like to switch to something more natural like Biest.
It might take a few tries but I'm sure you can get someone to prescribe it for you. This is exactly what a product like Biest is designed for. It's not off the map in the slightest.